Eupraxia Pharmaceuticals Stock
Eupraxia Pharmaceuticals Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- CEO
- James A. Helliwell
- Employees
- 49
- Market cap
- $616 M
- IPO
- 09/03/2021
Eupraxia Pharmaceuticals Inc. is a clinical-stage biopharmaceutical firm specializing in the discovery, advancement, and commercialization of innovative technologies. Its flagship compound, EP-104IAR, is currently in a Phase II clinical trial, targeting both critical unmet medical needs and pain management for knee…
Eupraxia Pharmaceuticals stock: price history
1D
-2.9%
1W
-12.0%
1M
-17.0%
6M
-4.0%
YTD
-9.4%
1Y
+14.6%
2Y
+175.0%
5Y
+231.6%
10Y
–
Next earnings date
Next earnings date
03/11/2026 (in 17 days)
Volatility around earnings
~5% stronger price swings than usual
Ask the agents about Eupraxia Pharmaceuticals
Analyst assessment of Eupraxia Pharmaceuticals
0
STRONG BUY
2
BUY
0
HOLD
0
SELL
0
STRONG SELL
2
TOTAL · Buy
As of: 01/10/2026
Eupraxia Pharmaceuticals stock metrics
P/E
-6.48
P/B
3.34
EV/EBITDA
-6.91
RETURN ON EQUITY
-10.8%
NET MARGIN
0.0%
DEBT/EQUITY
0.01
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
81.2%
FLOAT SHARES
53,523,804
AVG. DAILY VOLUME (30D)
91,727
Comparable stocks
Frequently asked questions about Eupraxia Pharmaceuticals stock
What does Eupraxia Pharmaceuticals do?
Eupraxia Pharmaceuticals Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in Canada.
The CEO is James A. Helliwell, the company employs around 49 people.
The IPO was on 09/03/2021; the stock trades on TSX under the ticker EPRX.TO.
What do analysts say about Eupraxia Pharmaceuticals stock?
2 analysts rate the stock, the consensus is Buy (as of 01/10/2026).
This is an external assessment, not a statement by Market Jury.
When does Eupraxia Pharmaceuticals report next?
The next earnings date is 03/11/2026.
Around past earnings, price swings were roughly 5% stronger than usual.
Does Eupraxia Pharmaceuticals pay a dividend?
No, Eupraxia Pharmaceuticals currently does not pay a dividend.
Which stocks are comparable to Eupraxia Pharmaceuticals?
Comparable stocks include AbCellera Biologics, Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines and Incyte.
How can I get Eupraxia Pharmaceuticals stock analyzed?
Clicking "Analyze stock" lets five strategies assess Eupraxia Pharmaceuticals against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.